The Ovation Fertility network of labs convinced a federal judge to toss a proposed class action alleging it deceptively marketed the efficacy of its preimplantation genetic tests.
The plaintiffs didn’t allege they “failed to become pregnant, suffered a miscarriage, or experienced a medically compromised pregnancy—notwithstandting Ovation’s alleged marketing statements” that the testing “mitigates all of those problems,” Judge Maryellen Noreika of the US District Court for the District of Delaware said Wednesday, rejecting the suit.
The plaintiffs were people seeking fertility treatments and had bought Ovation’s genetic tests for aneuploidy, a chromosomal disorder, before the implantation of embryos. Ovation ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.